Delta-Fly Pharma, Inc. (TYO:4598)

Japan flag Japan · Delayed Price · Currency is JPY
110.00
0.00 (0.00%)
Aug 6, 2026, 2:21 PM JST
Market Cap1.57B -76.8%
Revenue (ttm)n/a
Net Income-1.63B
EPS-140.37
Shares Out 14.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,500
Open110.00
Previous Close110.00
Day's Range108.00 - 111.00
52-Week Range92.00 - 722.00
Beta-0.71
Analystsn/a
Price Targetn/a
Earnings DateAug 7, 2026

About Delta-Fly Pharma

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 12
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4598
Full Company Profile

Financial Performance

Financial Statements